ADAPTIVE BIOTECHNOLOGIES CORPORATION Research and Development Expense
ADAPTIVE BIOTECHNOLOGIES CORPORATION (ADPT) reported Research and Development Expense of $19.15 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- ADAPTIVE BIOTECHNOLOGIES CORPORATION research and development expense for the quarter ending 2026-06-30 was $19.15M, a 20.64% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION research and development expense for the quarter ending 2026-03-31 was $23.62M, a 2.40% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION research and development expense for the quarter ending 2025-12-31 was $21.76M, a 6.16% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION research and development expense for the quarter ending 2025-09-30 was $23.67M, a 2.04% decline year-over-year.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION research and development expense for fiscal 2025 was $93.77M, a 8.92% decline from fiscal 2024.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION research and development expense for fiscal 2024 was $102.95M, a 15.69% decline from fiscal 2023.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION research and development expense for fiscal 2023 was $122.12M, a 13.85% decline from fiscal 2022.
- ADAPTIVE BIOTECHNOLOGIES CORPORATION research and development expense for fiscal 2022 was $141.76M, a 0.41% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.15M 10-Q · filed 2026-08-04 | $42.78M 10-Q · filed 2026-08-04 | $64.54M derived: sum of 3 quarters · filed 2026-08-04 | $88.21M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $23.62M 10-Q · filed 2026-05-05 | $45.39M derived: sum of 2 quarters · filed 2026-05-05 | $69.06M derived: sum of 3 quarters · filed 2026-05-05 | $93.19M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $21.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $45.43M derived: sum of 2 quarters · filed 2026-02-26 | $69.57M derived: sum of 3 quarters · filed 2026-08-04 | $93.77M 10-K · filed 2026-02-26 |
| 2025-09-30 | $23.67M 10-Q · filed 2025-11-05 | $47.80M derived: sum of 2 quarters · filed 2026-08-04 | $72.01M 10-Q · filed 2025-11-05 | $95.20M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $24.13M 10-Q · filed 2026-08-04 | $48.34M 10-Q · filed 2026-08-04 | $71.53M derived: sum of 3 quarters · filed 2026-08-04 | $95.69M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $24.20M 10-Q · filed 2026-05-05 | $47.40M derived: sum of 2 quarters · filed 2026-05-05 | $71.56M derived: sum of 3 quarters · filed 2026-05-05 | $96.91M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $23.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $47.35M derived: sum of 2 quarters · filed 2026-02-26 | $72.71M derived: sum of 3 quarters · filed 2026-02-26 | $102.95M 10-K · filed 2026-02-26 |
| 2024-09-30 | $24.16M 10-Q · filed 2025-11-05 | $49.52M derived: sum of 2 quarters · filed 2025-11-05 | $79.76M 10-Q · filed 2025-11-05 | $108.51M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $25.35M 10-Q · filed 2025-08-05 | $55.60M 10-Q · filed 2025-08-05 | $84.34M derived: sum of 3 quarters · filed 2026-02-26 | $112.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $30.25M 10-Q · filed 2025-05-01 | $58.99M derived: sum of 2 quarters · filed 2026-02-26 | $87.52M derived: sum of 3 quarters · filed 2026-02-26 | $119.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $28.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $57.28M derived: sum of 2 quarters · filed 2026-02-26 | $89.52M derived: sum of 3 quarters · filed 2026-02-26 | $122.12M 10-K · filed 2026-02-26 |
| 2023-09-30 | $28.53M 10-Q · filed 2024-11-07 | $60.77M derived: sum of 2 quarters · filed 2024-11-07 | $93.37M 10-Q · filed 2024-11-07 | $124.59M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-06-30 | $32.24M 10-Q · filed 2024-08-01 | $64.84M 10-Q · filed 2024-08-01 | $96.06M derived: sum of 3 quarters · filed 2025-03-03 | $131.72M derived: sum of 4 quarters · filed 2025-03-03 |
| 2023-03-31 | $32.60M 10-Q · filed 2024-05-07 | $63.82M derived: sum of 2 quarters · filed 2025-03-03 | $99.48M derived: sum of 3 quarters · filed 2025-03-03 | $136.52M derived: sum of 4 quarters · filed 2025-03-03 |
| 2022-12-31 | $31.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $66.88M derived: sum of 2 quarters · filed 2025-03-03 | $103.92M derived: sum of 3 quarters · filed 2025-03-03 | $141.76M 10-K · filed 2025-03-03 |
| 2022-09-30 | $35.66M 10-Q · filed 2023-11-09 | $72.69M derived: sum of 2 quarters · filed 2023-11-09 | $110.53M 10-Q · filed 2023-11-09 | $145.23M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $37.04M 10-Q · filed 2023-08-02 | $74.88M 10-Q · filed 2023-08-02 | $109.58M derived: sum of 3 quarters · filed 2024-02-29 | $145.65M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | $37.84M 10-Q · filed 2023-05-03 | $72.54M derived: sum of 2 quarters · filed 2024-02-29 | $108.61M derived: sum of 3 quarters · filed 2024-02-29 | $146.41M derived: sum of 4 quarters · filed 2024-02-29 |
| 2021-12-31 | $34.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $70.77M derived: sum of 2 quarters · filed 2024-02-29 | $108.57M derived: sum of 3 quarters · filed 2024-02-29 | $142.34M 10-K · filed 2024-02-29 |
| 2021-09-30 | $36.07M 10-Q · filed 2022-11-03 | $73.87M derived: sum of 2 quarters · filed 2022-11-03 | $107.64M 10-Q · filed 2022-11-03 | $143.47M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-06-30 | $37.80M 10-Q · filed 2022-08-03 | $71.57M 10-Q · filed 2022-08-03 | $107.40M derived: sum of 3 quarters · filed 2023-02-14 | $137.72M derived: sum of 4 quarters · filed 2023-02-14 |
| 2021-03-31 | $33.77M 10-Q · filed 2022-05-04 | $69.60M derived: sum of 2 quarters · filed 2023-02-14 | $99.92M derived: sum of 3 quarters · filed 2023-02-14 | $125.91M derived: sum of 4 quarters · filed 2023-02-14 |
| 2020-12-31 | $35.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-14 | $66.14M derived: sum of 2 quarters · filed 2023-02-14 | $92.14M derived: sum of 3 quarters · filed 2023-02-14 | $116.07M 10-K · filed 2023-02-14 |
| 2020-09-30 | $30.31M 10-Q · filed 2021-11-03 | $56.31M derived: sum of 2 quarters · filed 2021-11-03 | $80.24M 10-Q · filed 2021-11-03 | $101.43M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $25.99M 10-Q · filed 2021-08-04 | $49.93M 10-Q · filed 2021-08-04 | $71.12M derived: sum of 3 quarters · filed 2022-02-15 | $91.62M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | $23.93M 10-Q · filed 2021-05-05 | $45.12M derived: sum of 2 quarters · filed 2022-02-15 | $65.63M derived: sum of 3 quarters · filed 2022-02-15 | $82.16M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $21.19M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $41.70M derived: sum of 2 quarters · filed 2022-02-15 | $58.22M derived: sum of 3 quarters · filed 2022-02-15 | $70.70M 10-K · filed 2022-02-15 |
| 2019-09-30 | $20.51M 10-Q · filed 2020-11-10 | $37.03M derived: sum of 2 quarters · filed 2020-11-10 | $49.52M 10-Q · filed 2020-11-10 | $60.58M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $16.53M 10-Q · filed 2020-08-10 | $29.01M 10-Q · filed 2020-08-10 | $40.08M derived: sum of 3 quarters · filed 2021-02-24 | $49.86M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $12.48M 10-Q · filed 2020-05-12 | $23.55M derived: sum of 2 quarters · filed 2021-02-24 | $33.33M derived: sum of 3 quarters · filed 2021-02-24 | $42.78M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $11.07M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $20.85M derived: sum of 2 quarters · filed 2021-02-24 | $30.30M derived: sum of 3 quarters · filed 2021-02-24 | $39.16M 10-K · filed 2021-02-24 |
| 2018-09-30 | $9.78M 10-Q · filed 2019-11-12 | $19.23M derived: sum of 2 quarters · filed 2019-11-12 | $28.09M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $9.45M 10-Q · filed 2019-08-13 | $18.31M 10-Q · filed 2019-08-13 | ||
| 2017-12-31 | $32.00M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |